Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study.

Maritschnegg E, Wang Y, Pecha N, Horvat R, Van Nieuwenhuysen E, Vergote I, Heitz F, Sehouli J, Kinde I, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Speiser P, Zeillinger R.

J Clin Oncol. 2015 Dec 20;33(36):4293-300. doi: 10.1200/JCO.2015.61.3083. Epub 2015 Nov 9.

2.

Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.

Nair N, Camacho-Vanegas O, Rykunov D, Dashkoff M, Camacho SC, Schumacher CA, Irish JC, Harkins TT, Freeman E, Garcia I, Pereira E, Kendall S, Belfer R, Kalir T, Sebra R, Reva B, Dottino P, Martignetti JA.

PLoS Med. 2016 Dec 27;13(12):e1002206. doi: 10.1371/journal.pmed.1002206. eCollection 2016 Dec.

3.

The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.

Chang CC, Wang HC, Liao YP, Chen YC, Weng YC, Yu MH, Lai HC.

J Gynecol Oncol. 2018 Jan;29(1):e17. doi: 10.3802/jgo.2018.29.e17.

4.

KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.

Sadlecki P, Antosik P, Grzanka D, Grabiec M, Walentowicz-Sadlecka M.

Tumour Biol. 2017 Oct;39(10):1010428317733984. doi: 10.1177/1010428317733984.

PMID:
28992761
5.

Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.

Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih IeM, Kurman R, Dao F, Levine DA, Giuntoli R, Roden R, Eshleman JR, Carvalho JP, Marie SK, Papadopoulos N, Kinzler KW, Vogelstein B, Diaz LA Jr.

Sci Transl Med. 2013 Jan 9;5(167):167ra4. doi: 10.1126/scitranslmed.3004952.

6.

Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium.

Manavi M, Bauer M, Baghestanian M, Berger A, Kucera E, Pischinger K, Battistutti W, Czerwenka K.

Tumour Biol. 2001 Sep-Oct;22(5):299-309.

PMID:
11553860
7.

Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis.

Mills NE, Fishman CL, Scholes J, Anderson SE, Rom WN, Jacobson DR.

J Natl Cancer Inst. 1995 Jul 19;87(14):1056-60. Erratum in: J Natl Cancer Inst 1995 Nov 1;87(21):1643.

PMID:
7616596
8.

The results of gynecologic surveillance in families with hereditary nonpolyposis colorectal cancer.

Ketabi Z, Gerdes AM, Mosgaard B, Ladelund S, Bernstein I.

Gynecol Oncol. 2014 Jun;133(3):526-30. doi: 10.1016/j.ygyno.2014.03.012. Epub 2014 Mar 13.

PMID:
24631699
9.

REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer.

Jia W, Chang B, Sun L, Zhu H, Pang L, Tao L, Zou H, Du J, Dong Y, Qi Y, Jiang J, Liang W, Li F, Zhao X.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):5940-9. eCollection 2014.

10.

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.

Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ.

Gynecol Oncol. 2013 Sep;130(3):554-9. doi: 10.1016/j.ygyno.2013.06.019. Epub 2013 Jun 20.

11.

Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.

Meagher NS, Schuster K, Voss A, Budden T, Pang CNI, deFazio A, Ramus SJ, Friedlander ML.

Gynecol Oncol. 2018 Sep;150(3):527-533. doi: 10.1016/j.ygyno.2018.07.013. Epub 2018 Jul 25.

12.

Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor.

Fujiwara S, Nawa A, Nakanishi T, Shimoyama Y, Kajiyama H, Shibata K, Ino K, Nakamura S, Kikkawa F, Yatabe Y.

Hum Pathol. 2010 Apr;41(4):560-5. doi: 10.1016/j.humpath.2009.09.010. Epub 2009 Dec 11.

PMID:
20004952
13.

Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.

Kim YM, Lee SW, Chun SM, Kim DY, Kim JH, Kim KR, Kim YT, Nam JH, van Hummelen P, MacConaill LE, Hahn WC, Jang SJ.

PLoS One. 2014 Jun 17;9(6):e99451. doi: 10.1371/journal.pone.0099451. eCollection 2014.

14.

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK.

J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.

15.

The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.

Furlan D, Carnevali I, Marcomini B, Cerutti R, Dainese E, Capella C, Riva C.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3329-36.

16.

beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.

Moreno-Bueno G, Gamallo C, Pérez-Gallego L, de Mora JC, Suárez A, Palacios J.

Diagn Mol Pathol. 2001 Jun;10(2):116-22.

PMID:
11385321
17.

Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.

Erickson BK, Kinde I, Dobbin ZC, Wang Y, Martin JY, Alvarez RD, Conner MG, Huh WK, Roden RB, Kinzler KW, Papadopoulos N, Vogelstein B, Diaz LA Jr, Landen CN Jr.

Obstet Gynecol. 2014 Nov;124(5):881-5. doi: 10.1097/AOG.0000000000000484.

18.

Efficacy of liquid-based genetic diagnosis of endometrial cancer.

Matsuura M, Yamaguchi K, Tamate M, Satohisa S, Teramoto M, Iwasaki M, Sugita S, Hasegawa T, Koubo R, Takane K, Ikenoue T, Furukawa Y, Saito T.

Cancer Sci. 2018 Dec;109(12):4025-4032. doi: 10.1111/cas.13819. Epub 2018 Oct 26.

19.

Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.

De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J, Reis-Filho JS.

Mol Oncol. 2014 Feb;8(1):150-8. doi: 10.1016/j.molonc.2013.10.006. Epub 2013 Oct 31.

20.

Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia.

Zauber P, Denehy TR, Taylor RR, Ongcapin EH, Marotta S, Sabbath-Solitare M.

Int J Gynecol Cancer. 2015 Jun;25(5):863-8. doi: 10.1097/IGC.0000000000000421.

PMID:
25768080

Supplemental Content

Support Center